Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 72.2% in the first quarter, Holdings Channel reports. The institutional investor owned 2,549,572 shares of the company’s stock after buying an additional 1,069,400 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Amneal Pharmaceuticals were worth $32,405,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Kemnay Advisory Services Inc. acquired a new stake in Amneal Pharmaceuticals in the fourth quarter valued at about $26,000. Federated Hermes Inc. raised its stake in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after buying an additional 2,168 shares in the last quarter. Spire Wealth Management raised its stake in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares in the last quarter. Transamerica Financial Advisors LLC lifted its holdings in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after buying an additional 2,460 shares during the period. Finally, Comerica Bank grew its position in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $17.85 on Monday. The firm has a market cap of $5.69 billion, a PE ratio of 46.97 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a 12 month low of $7.66 and a 12 month high of $18.39. The firm has a 50 day simple moving average of $15.05 and a 200 day simple moving average of $13.90.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 17.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on AMRX. Barclays raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. UBS Group boosted their price target on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $16.60.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.